Cheelcare Inc (CHER) Q3 2026 earnings summary

Executive summary

• Achieved record quarterly revenue, driven by increased adoption and expanded distribution network.

• Surpassed 2,000 cumulative Companion units sold, reflecting strong market acceptance.

• Expanded global distribution to over 500 dealer locations, including top three North American networks.

• Health Canada issued a "Compliant" rating after inspection, validating quality management systems.

• Manufacturing operations scaled up to support higher commercial volumes.

Financial highlights

• Revenue for Q3 2026 was $549,857, a 16% increase compared to Q3 2025.

• Net revenue reached $470,614, up from $394,055 in Q3 2024.

• Gross profit rose to $208,630 (44.3% margin) from $123,317 (31.2% margin) in Q3 2025.

• Net loss widened to $(509,824), or $(0.02) per share, compared to $(310,083), or $(0.04) per share in Q3 2025, reflecting planned investments.

• Cash and cash equivalents stood at $83,642, with working capital of $355,047 as of January 31, 2026.

Outlook and guidance

• Anticipates updates on ADP and FDA 510(k) processes for Curio in Q2 or Q3 2026.

• Medicare and Medicaid eligibility for Companion expected to expand U.S. market access.

• Focus remains on scaling operations and supporting adoption as commercialization advances.